SWOG clinical trial number
EAY191-S3

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors

67% Accrual
Accrual
67%
Open
Phase
67% Accrual
Accrual
67%
Abbreviated Title
ComboMATCH S3
Status Notes
This study is open to participant enrollment effective 12pm PT on 3/6/2023.
Activated
03/06/2023

Research committees

comboMATCH
Immunomolecular Therapeutics

Treatment

Paclitaxel Ipatasertib

Reports & Approvals

Trial Locations

Other Clinical Trials

CTSU/A151804
SWOG Clinical Trial Number

ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS

Research Committee(s)
Immunomolecular Therapeutics
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Early Therapeutics & Rare Cancers
Activated
06/15/2020
Open
Phase